Bharat Biotech asserted the safety of its Covid-19 vaccine, Covaxin, citing various studies published in peer-reviewed journals. This statement followed a report in The Economic Times regarding adverse events of special interest (AESI) reported by participants in an observational study on Covaxin. The company emphasized the need for comprehensive safety data in such studies, including comparisons with non-vaccinated subjects and those receiving other vaccines.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.